Medtronic plc (NYSE:MDT) : The most positive equity analysts on Medtronic plc (NYSE:MDT) expects the shares to touch $98, whereas, the least positive believes that the stock will trade at $56 in the short term. The company is covered by 14 Wall Street Brokerage Firms. The average price target for shares are $88.11 with an expected fluctuation of $10.8 from the mean.
Shares of Medtronic plc rose by 1.17% in the last five trading days and 7.76% for the last 4 weeks. Medtronic plc is up 15.13% in the last 3-month period. Year-to-Date the stock performance stands at 13.38%.
Medtronic plc (NYSE:MDT) : Zacks Investment Research ranks Medtronic plc (NYSE:MDT) as 3, which is a Hold recommendation. 12 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 2 other analysts are mildly bullish on the stock and favor a Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 20 research analysts is 1.78, which indicates as a Buy.
Medtronic plc (NYSE:MDT): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $85.75 and $85.71 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $86.91. The buying momentum continued till the end and the stock did not give up its gains. It closed at $86.77, notching a gain of 1.54% for the day. The total traded volume was 6,355,632 . The stock had closed at $85.45 on the previous day.
In an insider trading activity, The officer (SrVP & Chief Scien, Clin, Reg), of Medtronic Plc, Kuntz Richard had unloaded 49,905 shares at $82.6 per share in a transaction on June 3, 2016. The total value of transaction was $4,122,153. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.